PPT-Dolutegravir ( Tivicay )

Author : brown | Published Date : 2024-01-29

Prepared by Brian R Wood MD David H Spach MD Last Updated January 28 2021 Dolutegravir Tivicay INSTI Tivicay TIVehkay Dolutegravir Treatment Naïve 50 mg once

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Dolutegravir ( Tivicay )" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Dolutegravir ( Tivicay ): Transcript

Prepared by Brian R Wood MD David H Spach MD Last Updated January 28 2021 Dolutegravir Tivicay INSTI Tivicay TIVehkay Dolutegravir Treatment Naïve 50 mg once daily with or without food. New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. Generic. HIV . Drugs. on 90-90-90. Esteban Burrone. Medicines Patent Pool. . . Impact in terms of treatment affordability. Impact in making new treatments available faster. Impact in making needed new formulations. Learning Objectives. EARLY VS DEFERRED ART. The Case is Made. Should Early-Stage Asymptomatic HIV Patients Receive ART? . The INSIGHT START Study. The CD4 Cell Count As a Measure . of Immune Deficiency in HIV Patients. New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action. IAS 2017 . Paris . 24. th. July 2017. Modelling the cost and cost-effectiveness of responses to . HIV drug resistance. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Heather Watts MD Director of HIV Prevention, Program Quality Team Office of the Global AIDS Coordinator Dolutegravir in PEPFAR HIV RNA < 50 copies/mL and CD4 response in the SINGLE trial J Acquir Immune *\n\b\n\t\t\t$\n\n$\b\t\b$ Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Panelists. Constance Benson. Hyman Scott. Annie . Luetkemeyer. Robert . Schooley. Financial Relationships With Commercial Entities. Linda Barlow-Mosha*. 1. , Grace Miriam . Ahimbisibwe. *. 1. , Elizabeth Chappell. 2. , Pauline Mary Amuge. 3. , . Annet. Nanduudu. 4. , Elizabeth Kaudha. 4. , Timothy Amukele. 5. , David Balamusani. –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.

Download Document

Here is the link to download the presentation.
"Dolutegravir ( Tivicay )"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.